免疫检查点抑制剂相关心血管免疫毒性的安全性荟萃分析
分析发现ICI暴露与6种心血管免疫相关不良事件风险升高相关,其中心肌炎(Peto OR 4.42,95%CI 1.56-12.50)和血脂异常(Peto OR 3.68,95%CI 1.89-7.19)风险较高。
要点
- ICI治疗与心肌炎、心包疾病、心力衰竭、血脂异常、心肌梗死及脑动脉缺血风险升高相关。
- 心肌炎和血脂异常的Peto OR分别为4.42和3.68,风险相对较高。
- 上述心血管免疫相关不良事件的发生率范围为每1000例患者3.2至19.3例。
核心结论
- 在随机对照试验中,ICI使用与6种心血管免疫相关不良事件相关,不限于心肌炎和心包炎。
研究设计与样本
- 系统综述与荟萃分析,检索ClinicalTrials.gov、Medline和Cochrane CENTRAL至2020年8月31日。
主要发现
- 在研究的16种心血管不良事件中,ICI使用与6种心血管免疫相关不良事件风险升高相关。
- 心肌炎Peto OR为4.42(95%CI 1.56-12.50,P<0.01;I2=0%,P=0.93)。
- 血脂异常Peto OR为3.68(95%CI 1.89-7.19,P<0.01;I2=0%,P=0.66)。
- 上述心血管免疫相关不良事件的发生率范围为每1000例患者3.2(95%CI 2.0-5.1)至19.3(95%CI 6.7-54.1),中位随访时间3.2至32.8个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown. METHODS AND RESULTS: We systematically reviewed all randomized clinical trials (RCTs) including at least one ICI-containing arm and available CV adverse event (CVAE) data in cancer patients in the ClinicalTrials.gov registry, Medline, and the Cochrane CENTRAL Register of Controlled Trials, up to 31 August 2020 (CRD42020165672). The primary outcome was the summary risk of 16 different CVAEs associated with ICI exposure vs. controls (placebo and non-placebo) in RCTs. CVAEs with an increased risk associated with ICI exposure were considered as CV irAEs. Summary incidences of CV irAEs identified in our primary outcome analyses were computed using all RCTs including at least one ICI-containing arm. We used a random-effects meta-analysis to obtain Peto odds ratios (ORs) with 95% confidence intervals (CIs) and logit transformation and inverse variance weighting to compute summary incidences. Sixty-three unique RCTs with at least one ICI-containing arm (32 518 patients) were retrieved, among which 48 (29 592 patients) had a control arm. Among the 16 CVAEs studied, ICI use was associated with an increased risk of 6 CV irAEs including myocarditis, pericardial diseases, heart failure, dyslipidemia, myocardial infarction, and cerebral arterial ischaemia with higher risks for myocarditis (Peto OR: 4.42, 95% CI: 1.56-12.50, P < 0.01; I2 = 0%, P = 0.93) and dyslipidemia (Peto OR: 3.68, 95% CI: 1.89-7.19, P < 0.01; I2 = 0%, P = 0.66). The incidence of these CVAEs ranged from 3.2 (95% CI 2.0-5.1) to 19.3 (6.7-54.1) per 1000 patients, in studies with a median follow-up ranging from 3.2 to 32.8 months. CONCLUSION: In RCTs, ICI use was associated with six CV irAEs, not confined to myocarditis and pericarditis.
引用
- Dolladille C, Akroun J, Morice PM, et al. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021. PMID: 34529770. doi:10.1093/eurheartj/ehab618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。